全文获取类型
收费全文 | 35302篇 |
免费 | 3061篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 382篇 |
儿科学 | 815篇 |
妇产科学 | 508篇 |
基础医学 | 4482篇 |
口腔科学 | 1141篇 |
临床医学 | 4635篇 |
内科学 | 7056篇 |
皮肤病学 | 694篇 |
神经病学 | 2792篇 |
特种医学 | 1308篇 |
外科学 | 4592篇 |
综合类 | 611篇 |
一般理论 | 32篇 |
预防医学 | 3885篇 |
眼科学 | 660篇 |
药学 | 2749篇 |
中国医学 | 34篇 |
肿瘤学 | 2075篇 |
出版年
2021年 | 466篇 |
2020年 | 302篇 |
2019年 | 508篇 |
2018年 | 524篇 |
2017年 | 401篇 |
2016年 | 498篇 |
2015年 | 580篇 |
2014年 | 770篇 |
2013年 | 1263篇 |
2012年 | 1762篇 |
2011年 | 1869篇 |
2010年 | 994篇 |
2009年 | 938篇 |
2008年 | 1687篇 |
2007年 | 1770篇 |
2006年 | 1828篇 |
2005年 | 1837篇 |
2004年 | 1694篇 |
2003年 | 1611篇 |
2002年 | 1638篇 |
2001年 | 1124篇 |
2000年 | 1108篇 |
1999年 | 969篇 |
1998年 | 433篇 |
1997年 | 388篇 |
1996年 | 328篇 |
1995年 | 341篇 |
1994年 | 270篇 |
1993年 | 285篇 |
1992年 | 691篇 |
1991年 | 740篇 |
1990年 | 665篇 |
1989年 | 606篇 |
1988年 | 558篇 |
1987年 | 543篇 |
1986年 | 540篇 |
1985年 | 542篇 |
1984年 | 405篇 |
1983年 | 367篇 |
1982年 | 291篇 |
1981年 | 281篇 |
1980年 | 218篇 |
1979年 | 376篇 |
1978年 | 270篇 |
1977年 | 245篇 |
1976年 | 208篇 |
1974年 | 253篇 |
1973年 | 233篇 |
1972年 | 205篇 |
1971年 | 217篇 |
排序方式: 共有10000条查询结果,搜索用时 453 毫秒
1.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
2.
Tonya J.H. White 《Journal of the American Academy of Child and Adolescent Psychiatry》2019,58(11):1042-1050
3.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
4.
5.
6.
7.
Nicole D. Facompre Pavithra Rajagopalan Varun Sahu Alexander T. Pearson Kathleen T. Montone Claire D. James Frederico O. Gleber-Netto Gregory S. Weinstein Jalal Jalaly Alexander Lin Anil K. Rustgi Hiroshi Nakagawa Joseph A. Califano Curtis R. Pickering Elizabeth A. White Bradford E. Windle Iain M. Morgan Roger B. Cohen Phyllis A. Gimotty Devraj Basu 《International journal of cancer. Journal international du cancer》2020,147(11):3236-3249
8.
9.
Jamaal L. Benjamin MD PhD Rebecca Dennis DO Stacy White Jr MD David Munson MD Sudha A. Anupindi MD Maciej Piskunowicz MD Kassa Darge MD PhD Ami Gokli MD Misun Hwang MD 《Journal of ultrasound in medicine》2020,39(5):1031-1036
Bowel diseases of prematurity, including necrotizing enterocolitis, are dreaded ailments of neonates. Early diagnosis is difficult, with clinical and radiographic findings often inconclusive. We present a novel use of contrast-enhanced ultrasound in detection of pediatric bowel disease. Early identification of compromised blood flow or an at-risk bowel can be quantitatively detected and monitored. This ability has implications for guidance of emerging therapies, allowing targeting of inflammation. These findings represent an advancement in detection of bowel disease in neonates. 相似文献